Fig. 2From: Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 studyFlow chart of study. Forty-four volunteers received AD16 in the 5 mg to 60 mg dose group of SAD. FAS, full analysis set; PKS, PK analysis set; SS, safety analysis set; FES, FE analysis setBack to article page